BRIEF published on 11/04/2024 at 11:51, 1 year 1 month ago Acticor Biotech : Publication des résultats financiers semestriels 2024 Résultats Semestriels Biotechnologie Finance Redressement Judiciaire Glenzocimab
BRIEF published on 11/04/2024 at 11:51, 1 year 1 month ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 1 month ago Informations privilégiées / Communiqué sur comptes, résultats Acticor Biotech publie ses résultats financiers semestriels 2024 et annonce le repositionnement du glenzocimab dans le traitement de l’infarctus du myocarde avec élévation du segment ST (STEMI) Résultats Financiers ACTICOR BIOTECH Glenzocimab Repositionnement Infarctus Du Myocarde
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 1 month ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 1 year 2 months ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
BRIEF published on 10/11/2024 at 17:50, 1 year 2 months ago Acticor Biotech fait progresser le Glenzocimab dans le traitement de l'infarctus du myocarde Essais Cliniques ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde Traitement Cardiovasculaire
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 2 months ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 2 months ago Informations privilégiées / Autres communiqués Repositionnement de glenzocimab dans le traitement de l'infarctus du myocarde par Acticor Biotech. Nouvelle étude de phase 2b LIBERATE et préparation de l'étude GLORIA Traitement Étude Clinique ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde
BRIEF published on 07/09/2024 at 20:50, 1 year 5 months ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 1 year 5 months ago Acticor Biotech publie ses résultats financiers pour 2023 Résultats Annuels Rapport Financier ACTICOR BIOTECH Glenzocimab Levée De Capitaux
Published on 12/19/2025 at 03:15, 4 hours 32 minutes ago Tactical Resources Announces Receipt Of Final Order Approving Arrangement With Plum Acquisition Corp. III
Published on 12/19/2025 at 01:10, 6 hours 37 minutes ago Ostrom Climate Exits Existing UPRIIS ERPA Arrangements
Published on 12/19/2025 at 01:00, 6 hours 47 minutes ago Sun Peak Metals Announces Completion of Acquisition of Saudi Discovery Company SPV Limited
Published on 12/19/2025 at 00:50, 6 hours 57 minutes ago High Resolution Gravity Survey Targets Challenger Repeats
Published on 12/19/2025 at 00:00, 7 hours 47 minutes ago LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor
Published on 12/19/2025 at 07:15, 31 minutes ago OPPO Collaborates with UNESCO, Leveraging Tablets to Empower Educational Equity and Digital Inclusion in Asia and Africa
Published on 12/19/2025 at 07:10, 37 minutes ago Deutsche Konsum REIT-AG publishes full year 2024/2025 results
Published on 12/19/2025 at 07:00, 46 minutes ago From Global Awards to a Global Stage: OPPO Photography Awards 2025 Conclude with Finale Exhibition in Egypt
Published on 12/19/2025 at 07:00, 47 minutes ago Branicks Group AG: Sale of the SAP Tower in Eschborn
Published on 12/19/2025 at 07:00, 47 minutes ago HORNBACH increases sales and market share in 9M 2025/26 and Q3 – adjusted EBIT down EUR 7.3 million in Q3, 9M at previous year’s level
Published on 12/19/2025 at 07:00, 47 minutes ago EURAZEO ANNONCE AVOIR MENÉ AVEC SUCCÈS UNE TRANSACTION ACCÉLÉRANT SA ROTATION D'ACTIFS
Published on 12/19/2025 at 07:00, 47 minutes ago EURAZEO ANNOUNCES A SUCCESSFUL TRANSACTION ACCELERATING ITS ASSET ROTATION
Published on 12/18/2025 at 18:30, 13 hours 17 minutes ago Schneider Electric completes transaction to acquire remaining 35% stake in existing Indian JV
Published on 12/18/2025 at 18:30, 13 hours 17 minutes ago Schneider Electric finalise l’opération d’acquisition des 35% restants du capital de sa JV existante en Inde
Published on 12/18/2025 at 17:45, 14 hours 2 minutes ago Cie du Bois Sauvage: Vernietiging eigen aandelen
